Frédéric FIORE

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

Frédéric FIORE, Frédéric Blanchard, F. Charbonnier et al. · British Journal of Cancer · 2007 · 734 citations · Full text

Medicine, Oncology, Pharmacology +17

Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation

A. Montagnoli, Frédéric FIORE, Esther Eytan et al. · Genes & Development · 1999 · 611 citations · Full text

Medicine, Molecular Biology, Oncology +15

Impact of FcγRIIa-FcγRIIIa Polymorphisms and <i>KRAS</i> Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

Frédéric Bibeau, Evelyne Lopez‐Crapez, Frédéric FIORE et al. · Journal of Clinical Oncology · 2009 · 512 citations

Medicine, Oncology, Pharmacology +16

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez et al. · JAMA Oncology · 2022 · 324 citations · Full text

Medicine, Oncology, Surgery +14